Zheng, J., Zhou, J., W, Y., Shi, J. (2026). Practical prognostic tool for personalising first-line alectinib in ALK-positive NSCLC: A real-world model integrating neutrophil-to-lymphocyte ratio, lactate dehydrogenase, and eosinophil count.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e20743